Want to see ALGS full AI Analyst Report?
ALGS Stock Chart & Stats
$7.47
-$0.61(-13.01%)
At close: 4:00 PM EDT
$7.47
-$0.61(-13.01%)
Day’s Range― - ―
52-Week Range$3.98 - $13.69
Previous CloseN/A
Volume203.10K
Average Volume (3M)94.42K
Market Cap
$32.72M
Enterprise Value$33.27
Total Cash (Recent Filing)$30.38M
Total Debt (Recent Filing)$3.50M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Mar 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.30
Shares Outstanding5,444,558
10 Day Avg. Volume32,651
30 Day Avg. Volume94,425
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$72.50Price Target Upside870.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-6.3
Revenue Forecast (FY)$35.99M
Bulls Say, Bears Say
Bulls Say
High Gross MarginThe roughly 89% TTM gross margin indicates that reported revenue carries substantial economic value before operating expenses. If the company scales revenue from future products or collaborations, this margin profile could support better operating leverage, although current revenue remains limited.
Modest LeverageLow debt relative to equity reduces refinancing and solvency pressure compared with more leveraged biotechnology peers. This provides some balance-sheet flexibility over the next several months, although volatile equity and accumulated losses remain meaningful constraints on financial resilience.
Governance OversightRecent shareholder approvals reinforce board continuity, independent audit oversight, and recurring input on executive compensation. Removing the evergreen feature also makes equity incentives more controlled, which may improve governance discipline and limit automatic dilution from the employee plan.
Bears Say
Persistent Losses And Revenue DeclineRecurring operating and net losses show that the current expense base is far too large for the company’s revenue scale. The approximately 20.5% TTM revenue decline further weakens operating leverage, making a durable path to profitability dependent on stronger future development or commercial outcomes.
Heavy Cash BurnMaterially negative operating and free cash flow indicate that the business is consuming substantial cash rather than funding operations internally. Because free cash flow closely tracks net loss, the losses translate into real liquidity needs, increasing dependence on future financing or other capital sources.
No Commercialized Product RevenueThe absence of approved commercial products means the company lacks recurring product-sale revenue to support its research and clinical activities. Reliance primarily on financing creates ongoing capital-raising needs and leaves the business exposed to dilution or funding pressure before candidates can generate durable sales.
Aligos Therapeutics News
ALGS FAQ
What was Aligos Therapeutics’s price range in the past 12 months?
Aligos Therapeutics lowest stock price was $3.98 and its highest was $13.69 in the past 12 months.
What is Aligos Therapeutics’s market cap?
Aligos Therapeutics’s market cap is $32.72M.
When is Aligos Therapeutics’s upcoming earnings report date?
Aligos Therapeutics’s upcoming earnings report date is Mar 11, 2027 which is in 172 days.
How were Aligos Therapeutics’s earnings last quarter?
Aligos Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$1.094 by $0.954.
Is Aligos Therapeutics overvalued?
According to Wall Street analysts Aligos Therapeutics’s price is currently Undervalued.
Does Aligos Therapeutics pay dividends?
Aligos Therapeutics does not currently pay dividends.
What is Aligos Therapeutics’s EPS estimate?
Aligos Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Aligos Therapeutics have?
Aligos Therapeutics has 5,444,558 shares outstanding.
What happened to Aligos Therapeutics’s price movement after its last earnings report?
Aligos Therapeutics reported an EPS of -$0.14 in its last earnings report, beating expectations of -$1.094. Following the earnings report the stock price went up 16.245%.
Which hedge fund is a major shareholder of Aligos Therapeutics?
Currently, no hedge funds are holding shares in ALGS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Aligos Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$72.50 (870.55% Upside)
$72.50 (870.55% Upside)
Blogger Sentiment
Bullish
ALGS Sentiment 100%
Sector Average 63%
Sector Average 63%
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.54%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-50.76%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Aligos Therapeutics
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-antigen transport-inhibiting oligonucleotide polymer, which is currently undergoing Phase Ib clinical trials for chronic hepatitis B (CHB). Another asset for CHB, ALG-000184, a capsid assembly modulator, is progressing through Phase I clinical trials. Additionally, Aligos is advancing ALG-020572, an antisense oligonucleotide designed to stop HBsAg translation and secretion. Its portfolio also features siRNA drug candidates, including ALG-125755, ALG-125097, and ALG-125819, which have demonstrated potent capabilities in inhibiting HBsAg release from HBV-infected cells. For non-alcoholic steatohepatitis (NASH), the company is developing ALG-055009, a small molecule THR-ß agonist, now in Phase 1a/1b studies. Aligos has also forged several strategic alliances. These include licensing and collaboration with Luxna Biotech Co., Ltd. for HBV genome-targeting oligonucleotides, a partnership with Emory University for HBV capsid assembly modulator technology, an agreement with Katholieke Universiteit Leuven for the development of coronavirus protease inhibitors, and a deal with Merck to research and develop NASH-focused oligonucleotides. Established in 2018, Aligos Therapeutics is headquartered in South San Francisco, California.
ALGS Stock 12 Month Forecast
Average Price Target
$72.50
▲(870.55% Upside)
Technical Analysis
Medicinova
―
Celularity
―
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―
Ownership Overview
46.67%
Insiders
4.22% Mutual Funds
31.17% Other Institutional Investors
14.58% Public Companies and
Individual Investors